Phase 1b/2 trial of BI 836845, an insulin-like growth factor (IGF) ligand-neutralising antibody, in combination with exemestane and everolimus in postmenopausal women with hormone receptor-positive, locally advanced or metastatic breast cancer: Preliminary results of the Phase 1b part

被引：0

作者：

Cortes, J. ^{[1
,2
]}

Martinez Janesz, N. ^{[1
]}

Sablin, M. P. ^{[3
]}

Perez-Fidalgo, J. A. ^{[4
]}

Neven, P. ^{[5
]}

Hedayati, E. ^{[6
,7
]}

Ballester, A. ^{[8
]}

Ehrhart, M. P. ^{[9
,10
]}

Huang, D. Chin-Lun ^{[11
]}

Bogenrieder, T. ^{[12
]}

Schmid, P. ^{[13
]}

机构：

[1] Ramon y Cajal Univ Hosp, Dept Med Oncol, Madrid, Spain

[2] Vall dHebron Inst Oncol VHIO, Dept Oncol, Barcelona, Spain

[3] Inst Curie, Dept Med Oncol, Paris, France

[4] Hosp Clin Univ Valencia, Dept Haematol & Med Oncol, Valencia, Spain

[5] UZ Leuven, Multidisciplinary Breast Ctr, Leuven, Belgium

[6] Karolinska Inst, Stockholm, Sweden

[7] Univ Hosp, Dept Oncol Pathol, Stockholm, Sweden

[8] Boehringer Ingelheim Espana SA, Dept Med Oncol, Barcelona, Spain

[9] Staburo GmbH, Munich, Germany

[10] Boehringer Ingelheim Pharma GmbH & Co KG, St Joseph, MO USA

[11] Boehringer Ingelheim Taiwan Ltd, Med, Taipei, Taiwan

[12] Boehringer Ingelheim RCV, Med, Vienna, Austria

[13] Queen Mary Univ London, Ctr Expt Canc Med, Barts Canc Inst, London, England

来源：

EUROPEAN JOURNAL OF CANCER | 2016年 / 57卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

389

引用

页码：S112 / S112

页数：1

共 50 条

[21] Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study
Layman, Rachel M.
Han, Hyo S.
Rugo, Hope S.
Stringer-Reasor, Erica M.
Specht, Jennifer M.
Dees, Claire
Kabos, Peter
Suzuki, Samuel
Mutka, Sarah C.
Sullivan, Brian F.
Gorbatchevsky, Igor
Wesolowski, Robert
LANCET ONCOLOGY, 2024, 25 (04): : 474 - 487
[22] Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain
E. Ciruelos
M. Vidal
E. Martínez de Dueñas
N. Martínez-Jáñez
Y. Fernández
J. A. García-Sáenz
L. Murillo
F. Carabantes
A. Beliera
R. Fonseca
J. Gavilá
Clinical and Translational Oncology, 2018, 20 : 753 - 760
[23] PALVEN: phase 1b trial of palbociclib, letrozole and venetoclax in estrogen receptor- and BCL2-positive advanced breast cancer
Muttiah, Christine
Whittle, James R.
Oakman, Catherine
Lindeman, Geoffrey J.
FUTURE ONCOLOGY, 2022, 18 (15) : 1805 - 1816
[24] Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain
Ciruelos, E.
Vidal, M.
Martinez de Duenas, E.
Martinez-Janez, N.
Fernandez, Y.
Garcia-Saenz, J. A.
Murillo, L.
Carabantes, F.
Beliera, A.
Fonseca, R.
Gavila, J.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2018, 20 (06): : 753 - 760
[25] Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer
Ibrahim, Nuhad K.
Yariz, Kemal O.
Bondarenko, Ihor
Manikhas, Alexei
Semiglazov, Vladimir
Alyasova, Anna
Komisarenko, Volodymyr
Shparyk, Yaroslav
Murray, James Lee
Jones, David
Senderovich, Shai
Chau, Albert
Erlandsson, Fredrik
Acton, Gary
Pegram, Mark
CLINICAL CANCER RESEARCH, 2011, 17 (21) : 6822 - 6830
[26] Alpelisib plus letrozole in estrogen receptor-Positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC): Safety and preliminary efficacy analysis from a phase 1b trial
Juric, Dejan
Goncalves, Anthony
Hamilton, Erika
Boni, Valentina
Mayer, Ingrid A.
Turri, Sabine
Wang, Yingbo
Vogl, Florian D.
Sellami, Dalila
Campone, Mario
CANCER RESEARCH, 2018, 78 (04)
[27] XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease
Peter Schmid
Javier Cortes
Ana Joaquim
Noelia Martínez Jañez
Serafín Morales
Tamara Díaz-Redondo
Sibel Blau
Patrick Neven
Julie Lemieux
José Ángel García-Sáenz
Lowell Hart
Tsvetan Biyukov
Navid Baktash
Dan Massey
Howard A. Burris
Hope S. Rugo
Breast Cancer Research, 25
[28] XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease
Schmid, Peter
Cortes, Javier
Joaquim, Ana
Janez, Noelia Martinez
Morales, Serafin
Diaz-Redondo, Tamara
Blau, Sibel
Neven, Patrick
Lemieux, Julie
Garcia-Saenz, Jose Angel
Hart, Lowell
Biyukov, Tsvetan
Baktash, Navid
Massey, Dan
Burris, Howard A., III
Rugo, Hope S.
BREAST CANCER RESEARCH, 2023, 25 (01)
[29] Interim Results from a Phase 1b/2a Study of Trastuzumab Emtansine and Docetaxel, With and Without Pertuzumab, in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer
Martin, M.
Garcia-Saenz, J. A.
Dewar, J. A.
Albanell, J.
Limentani, S. A.
Strasak, A.
Patre, M.
Branle, F.
Fumoleau, P.
CANCER RESEARCH, 2012, 72
[30] A phase 1b/2 trial of SHR-1701 in combination with gemcitabine and nab-paclitaxel in patients with untreated locally advanced or metastatic pancreatic cancer.
Zhou, Jun
Yu, Xianjun
Li, Zhihua
Zhou, Yuhong
Li, Jialin
Xue, Ran
Xia, Ye
Han, Hongxia
Wu, Yiwen
Shen, Lin
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16264 - E16264

← 1 2 3 4 5 →